Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine

Clinical Pharmacology and Therapeutics

Volumn 58, Issue 5, 1995, Pages 492-497

  Wu, Chi Yuan ^a,b,c,d   Benet, Leslie Z ^a,b,c,d   Hebert, Mary F ^a,b,c,d   Gupta, Suneel K ^a,b,c,d   Rowland, Malcolm ^a,b,c,d   Gomez, Denise Y ^a,b,c,d   Wacher, Vincent J ^a,b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ALZA CORPORATION   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d AvMax Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A;

BIOAVAILABILITY; DRUG ABSORPTION; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; INTESTINE; LIVER; LIVER METABOLISM; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SHORT SURVEY; THEORETICAL STUDY;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; COMPARATIVE STUDY; CYCLOSPORINE; DRUG INTERACTIONS; ERYTHROMYCIN; HUMAN; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; INTESTINES; KETOCONAZOLE; KIDNEY TRANSPLANTATION; LIVER; PROTEIN SYNTHESIS INHIBITORS; RIFAMPIN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028820208     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1016/0009-9236(95)90168-X     Document Type: Article

References (10)